D-0345-2025 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0345-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 13, 2025 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 16, 2025
Initiation Date
Mar 13, 2025
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Saxagliptin Tablets, USP, 2.5mg, a). 30-count bottle (NDC# 68462-726-30), b).90-count bottle(NDC# 68462-726-90), Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ 07430.

Reason for recall

CGMP Deviations

Distribution pattern

U.S. Nationwide

Code information

30-Count Bottle Lots: 17241788, exp. date Sep-26 17241821, exp. date Sep-26 17241822, exp. date Sep-26 90-Count Bottle Lot: 17241822, exp. date Sept 26

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0345-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0345-2025. Report a data issue: hello@regdatalab.com.